PT  - JOURNAL ARTICLE
AU  - Williamson, Maia Kavanagh
AU  - Hamilton, Fergus
AU  - Hutchings, Stephanie
AU  - Pymont, Hannah M.
AU  - Hackett, Mark
AU  - Arnold, David
AU  - Maskell, Nick A
AU  - MacGowan, Alasdair
AU  - Albur, Mahableshwar
AU  - Jenkins, Megan
AU  - Heys, Izak
AU  - Knapper, Francesca
AU  - Elsayed, Mustafa
AU  - Milligan, Rachel
AU  - ,
AU  - Muir, Peter
AU  - Vipond, Barry
AU  - Matthews, David A
AU  - Moran, Ed
AU  - Davidson, Andrew D.
TI  - Chronic SARS-CoV-2 infection and viral evolution in a hypogammaglobulinaemic individual
AID  - 10.1101/2021.05.31.21257591
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.31.21257591
4099  - http://medrxiv.org/content/early/2021/06/04/2021.05.31.21257591.short
4100  - http://medrxiv.org/content/early/2021/06/04/2021.05.31.21257591.full
AB  - There is widespread interest in the capacity for SARS-CoV-2 evolution in the face of selective pressures from host immunity, either naturally acquired post-exposure or from vaccine acquired immunity. Allied to this is the potential for long perm persistent infections within immune compromised individuals to allow a broader range of viral evolution in the face of sub-optimal immune driven selective pressure. Here we report on an immunocompromised individual who is hypogammaglobulinaemic and was persistently infected with SARS-CoV-2 for over 290 days, the longest persistent infection recorded in the literature to date. During this time, nine samples of viral nucleic acid were obtained and analysed by next-generation sequencing. Initially only a single mutation (L179I) was detected in the spike protein relative to the prototypic SARS-CoV-2 Wuhan-Hu-1 isolate, with no further changes identified at day 58. However, by day 155 the spike protein had acquired a further four amino acid changes, namely S255F, S477N, H655Y and D1620A and a two amino acid deletion (ΔH69/ΔV70). Infectious virus was cultured from a nasopharyngeal sample taken on day 155 and next-generation sequencing confirmed that the mutations in the virus mirrored those identified by sequencing of the corresponding swab sample. The isolated virus was susceptible to remdesivir in vitro, however a 17-day course of remdesivir started on day 213 had no effect on the viral RT-PCR cycle threshold (Ct) value. On day 265 the patient was treated with the combination of casirivimab and imdevimab. The patient experienced progressive resolution of all symptoms over the next 8 weeks and by day 311 the virus was no longer detectable by RT-PCR. The ΔH69/ΔV70 deletion in the N-terminus of the spike protein which arose in our patient is also present in the B.1.1.7 variant of concern and has been associated with viral escape mutagenesis after treatment of another immunocompromised patient with convalescent plasma. Our data confirms the significance of this deletion in immunocompromised patients but illustrates it can arise independently of passive antibody transfer, suggesting the deletion may be an enabling mutation that compensates for distant changes in the spike protein that arise under selective pressure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe DISCOVER study was funded by the Southmead Hospital Charity. Immunological work was funded by an Elizabeth Blackwell Institute TRACK award. A.D.D. / D.A.M are supported by the United States Food and Drug Administration (HHSF223201510104C) and the UK Research and Innovation / Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (grants MR/V027506/1 and BB/V013874/1). M.K.W is supported by MRC grant MR/V027506/1 (awarded to A.D.D). COG-UK is supported by funding from the MRC part of UKRI, the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. The authors would like to acknowledge support of the University of Bristol's Alumni and Friends, which funded the ImageXpress Pico Imaging System.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The DISCOVER study was ethically approved via the South Yorks REC (ref: 20/YH/0121, CRN approval no: 45469). The patient provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data referred to in the manuscript is available through GISAID or the European Nucleotide Archive database. www.gisaid.org www.ebi.ac.uk/ena